Contemporary use of prasugrel in clinical practice : Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium

Circulation: Cardiovascular Quality and Outcomes

Volumn 6, Issue 3, 2013, Pages 293-298

  Sandhu, Amneet ^a,b   Seth, Milan ^a   Dixon, Simon ^c   Share, David ^d   Wohns, David ^e   LaLonde, Thomas ^f   Moscucci, Mauro ^g   Riba, Arthur L ^h   Grossman, Michael ^a,b   Gurm, Hitinder S ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c WILLIAM BEAUMONT HOSPITAL   (United States)

^d Blue Cross Blue Shield of Michigan   (United States)

^e Frederik Meijer Heart and Vascular Institute   (United States)

^f ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h Oakwood Healthcare Inc   (United States)

Author keywords

Acute coronary syndromes; Coronary revascularization; Stents

Indexed keywords

CLOPIDOGREL; PRASUGREL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; BLUE CROSS BLUE SHIELD; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL PRACTICE; DRUG CONTRAINDICATION; DRUG INDUCED DISEASE; DRUG USE; FEMALE; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; INAPPROPRIATE PRESCRIBING; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRESCRIPTION; PRIORITY JOURNAL; SENESCENCE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRANSIENT ISCHEMIC ATTACK; UNITED STATES; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE;

ACUTE CORONARY SYNDROMES; CORONARY REVASCULARIZATION; STENTS;

ACUTE CORONARY SYNDROME; AGED; BLUE CROSS BLUE SHIELD INSURANCE PLANS; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; FEMALE; GUIDELINE ADHERENCE; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MICHIGAN; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PHYSICIAN'S PRACTICE PATTERNS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; QUALITY IMPROVEMENT; QUALITY INDICATORS, HEALTH CARE; REGISTRIES; RISK FACTORS; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84884472124     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.111.000060     Document Type: Article

References (11)

1. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015.
2. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E; PRINCIPLETIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116:2923-2932.
3. Wright R, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger EM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011; 57:1920-1959.
4. Effient (prasugrel) tablets: package insert. Indianapolis, IN: Eli Lilly and Company, 2010.
5. Gurm HS, Smith DE, Collins JS, Share D, Riba A, Carter AJ, LaLonde T, Kline-Rogers E, O'Donnell M, Changezi H, Zughaib M, Safian R, Moscucci M; Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention. J Am Coll Cardiol. 2008;51:529-535.
6. Kline-Rogers E, Share D, Bondie D, Rogers B, Karavite D, Kanten S, Wren P, Bodurka C, Fisk C, McGinnity J, Wright S, Fox S, Eagle KA, Moscucci M; Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Development of a multicenter interventional cardiology database: the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) experience. J Interv Cardiol. 2002;15: 387-392.
7. Moscucci M, Share D, Kline-Rogers E, O'Donnell M, Maxwell-Eward A, Meengs WL, Clark VL, Kraft P, De Franco AC, Chambers JL, Patel K, McGinnity JG, Eagle KA; Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). The Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) collaborative quality improvement initiative in percutaneous coronary interventions. J Interv Cardiol. 2002;15:381-386.
8. Gualano SK, Gurm HS, Share D, Smith D, Aronow HD, LaLonde T, Bates ER, Changezi H, McNamara R, Moscucci M. Temporal trends in the use of drug-eluting stents for approved and off-label indications: a longitudinal analysis of a large multicenter percutaneous coronary intervention registry. Clin Cardiol. 2010;33:111-116.
9. Roe MT, Armstrong PW, Fox KAA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng C, Merkely B, Gasparovic V, Corbalan R, Cintenza M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM; Trilogy ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. Accessed August 26, 2012. DOI: 10.1056/NEJMoa1205512.
10. Chin CT, Roe MT, Fox KAA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, Ohman EM. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J. 2010;160:16-22.
11. Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, Chandna H, Macias W, McCabe CH, Braunwald E. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol. 2008;51:2028-2033.